Hannes Hahne, OmicScouts

Preclinical stages in the drug discovery process require a multitude of biochemical and genetic assays in order to characterize the effects of drug candidates on cellular systems and model organisms. The identification and deconvolution of drug targets and off-targets remains a key challenge in both phenotypic screening- as well as target-based drug discovery.

Here, we will compare and contrast the most prominent and emerging proteomic approaches for target identification and deconvolution for specific compound classes, such as kinase or HDAC inhibitors or protein degraders (PROTACs, IMiDs and alikes), as well as generic target-class agnostic approaches.